JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB157420

Anti-Amikacin antibody

Be the first to review this product! Submit a review

|

(1 Publication)

Sheep Polyclonal Amikacin antibody. Suitable for ELISA, cELISA and reacts with Chemical samples. Cited in 1 publication. Immunogen corresponding to Chemical / Small Molecule corresponding to Amikacin.

Key facts

Host species

Sheep

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Applications

ELISA, cELISA

applications

style
left-column

Complementary Products

Primary Antibodies

AB171356

Anti-Human IgG3 antibody [EPR4419] - BSA and Azide free

RabMAb|Recombinant

Western blot - Anti-Human IgG3 antibody [EPR4419] - BSA and Azide free (AB171356)

  • 0
  • 0
Primary Antibodies

AB176594

Anti-ZZEF1 antibody

Immunoprecipitation - Anti-ZZEF1 antibody (AB176594)

  • 0
  • 0
Primary Antibodies

AB273052

Anti-ZWINT antibody [EPR23440-96] - BSA and Azide free

BOND RX™ Validated|RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-ZWINT antibody [EPR23440-96] - BSA and Azide free (AB273052)

  • 0
  • 0
Primary Antibodies

AB254715

Anti-ZNF503 antibody

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-ZNF503 antibody (AB254715)

  • 0
  • 0
style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "ELISA" : {"fullname" : "ELISA", "shortname":"ELISA"}, "cELISA" : {"fullname" : "Competitive ELISA", "shortname":"cELISA"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Chemical": { "ELISA-species-checked": "guaranteed", "ELISA-species-dilution-info": "", "ELISA-species-notes": "<p>Microtitre plate based.</p>", "cELISA-species-checked": "guaranteed", "cELISA-species-dilution-info": "", "cELISA-species-notes": "<p>10 ng/ml amikacin produces 60% inhibition.</p>" } } }
style
left-column
style
left-column

Properties and storage information

Form
Liquid
Purity
IgG fraction
Storage buffer
pH: 7.2 Preservative: 0.09% Sodium azide Constituents: 99% Phosphate Buffer, 0.88% Sodium chloride
Shipped at conditions
Blue Ice
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Amikacin is an aminoglycoside antibiotic with alternative names like amicasil and amikavet. It acts by binding irreversibly to the 30S ribosomal subunit which leads to the inhibition of protein synthesis in bacterial cells. The molecular weight of amikacin is about 585.6 daltons. This compound is widely utilized in the treatment of severe bacterial infections due to its effectiveness against gram-negative bacteria. In terms of expression amikacin is not expressed in a biological sense as it is a synthetic compound used as a pharmaceutical agent.
Biological function summary

The mechanism of action of amikacin disrupts the pathogenesis of bacteria by preventing proper protein assembly leading to bacterial death. It is not part of any biological complex but targets ribosomal structures within bacterial cells. Its interference with bacterial protein translation makes it an effective option against infections that other antibiotics may not address due to resistance.

Pathways

The bactericidal effect of amikacin does not fit into traditional human cellular pathways as it targets prokaryotic ribosomal subunits. However its role can indirectly affect human immune response pathways such as those activating phagocytes to clear the bacteria. In the context of bacterial resistance mechanisms proteins like aminoglycoside modifying enzymes may alter amikacin to neutralize its antibacterial activity.

Amikacin is mainly used to treat conditions such as severe systemic and urinary tract infections caused by susceptible strains including Pseudomonas aeruginosa and Escherichia coli. When resistance develops in bacterial pathogens related proteins like the aforementioned aminoglycoside modifying enzymes play a significant role in altering the drug's effectiveness leading to treatment challenges.
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

See full target information Amikacin
style
left-column

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Therapeutic advances in respiratory disease 14:1753466620905280 PubMed32270742

2020

Lymphocyte senescence in COPD is associated with decreased sirtuin 1 expression in steroid resistant pro-inflammatory lymphocytes.

Applications

Unspecified application

Species

Unspecified reactive species

Greg Hodge,Hai B Tran,Paul N Reynolds,Hubertus Jersmann,Sandra Hodge
View all publications
style
left-column
style
left-column
style
right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com